HR
BPMC

Howe & Rusling’s Blueprint Medicines BPMC Stock Holding History

Howe & Rusling’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-14
Closed -$1K – 782
2019
Q4 		$1K Hold
14
– – ﹤0.01% 729
2019
Q3 		$1K Hold
14
– – ﹤0.01% 741
2019
Q2 		$1K Hold
14
– – ﹤0.01% 720
2019
Q1 		$1K Buy
+14
New +$1.03K ﹤0.01% 718

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Howe & Rusling's BPMC Position: Q1 2020 in Review

Howe & Rusling sold out of Blueprint Medicines (BPMC) in Q1 2020, closing a stake of 14 shares — an estimated $1K sold.

Howe & Rusling first reported a position in BPMC in Q1 2019 and held it in 4 quarters. The position peaked at $1K in Q4 2019. 213 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

  • Howe & Rusling reported no remaining Blueprint Medicines position as of Q1 2020 after selling out during the quarter.
  • Howe & Rusling sold 14 Blueprint Medicines shares in Q1 2020, an estimated $1K.
  • Howe & Rusling first reported a position in Blueprint Medicines in Q1 2019 and held it in 4 quarters.
  • Howe & Rusling's Blueprint Medicines position peaked at $1K in Q4 2019.
  • 213 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Howe & Rusling's 13F filing for Q1 2020, filed 14 May 2020.